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Abstract
Background: Performance status (PS) assessment is an integral part of the decision-making process in cancer care.
Karnofsky Performance Status (KPS) and Eastern Cooperative Oncology Group (ECOG) PS are the most widely used
tools. In some studies, the absolute agreement rate of these tools between observers has been moderate to low.
The present study aimed to evaluate the inter-observer reliability and construct validity of the new Functionality
Assessment Flowchart (FAF) and compare it with ECOG PS and KPS in a sample of cancer patients.
Methods: The patients were recruited by convenience from the waiting rooms of the Breast and Gynecology
Ambulatory in a cross-sectional study. Two trained medical students (observer A) and five medical oncologists
(observers B) independently rated women according to the ECOG PS, KPS and FAF. After the determining the PS
scores, observer A administered the Functional Assessment of Cancer Therapy-Fatigue (FACT-F) questionnaire to
the participants. The agreements between observers A and B were investigated using the absolute agreement
rate (%), weighted and unweighted kappa and Spearman’s correlation test. For construct validity, the PS scores
were correlated with functional and fatigue scores by performing correlation analysis.
Results: Eighty women with a median age of 57 years were included in the study (86 % accrual rate). Among
these women, 39 (48.8 %) had advanced cancer. The overall absolute agreement rate between observers was 49.4 %
for KPS, 67 % for ECOG PS, and 78.2 % for FAF. When using unweighted kappa values, the inter-observer reliability was
“fair”, “moderate” and “substantial” for KPS, ECOG PS and FAF, respectively. However, when using weighted kappa
statistics, “substantial” agreement was observed for KPS and ECOG PS and “nearly perfect” agreement was observed for
FAF. All of the PS scales correlated very well with the functional and fatigue scores.
Conclusions: We present a new instrument with moderate to high inter-observer agreement and adequate construct
validity to measure PS in cancer patients.
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Background
Performance status (PS) is an assessment of the pa-
tients’ actual level of function, ability for self-care and
level of ambulation [1]. PS scales are used as selection
criteria and for the stratification of subgroups in clin-
ical trials. They are also used to evaluate the impact of
cancer treatments on health-related quality of life and
as an outcome measure to compare differences in the
functional performance before and after exposure to a
specific therapy [2]. Moreover, a patient’s PS score is
widely used as an aid in the decision to receive antican-
cer treatment or palliative care only [3].
The Karnofsky Performance Status (KPS) was intro-
duced in 1949 by Karnofsky and Burchenal [4] as an
11-point measure of the functional status, ranging from
0 % (death) to 100 % (normal functioning). The Eastern
Cooperative Oncology Group (ECOG) PS was devel-
oped as an alternative and easier PS assessment tool
[5]. By having fewer response options (from 0 to 5), the
ECOG PS is better than KPS in terms of inter-observer
agreement; however, the ECOG PS likely did not retain
the ability to more comprehensively detail a patient’s
PS [6]. The Palliative Performance Scale (PPS) was pro-
posed in 1996 to measure the PS of patients undergoing
palliative care [7]. The PPS was created as an alternative
to KPS in an attempt to improve the assessment of PS of
low-functional palliative-care patients. Among the PS
evaluation scales in oncology, the KPS, ECOG PS and
more recently, PPS are the most widely used [8].
Although these scales are widely used in the clinical
decision-making process in practice and research set-
tings, information on inter-observer agreement is scarce
and mostly dates from the 1980s. Regarding the rates of
absolute agreement between the raters, recent papers
have reported contradictory findings [1, 9]. Moderate to
high concordance rates were found for KPS (63–75 %)
and ECOG PS (90–92 %) in a study that included patients
with better-functioning scores [1]; however, another study
[9] found low absolute agreement rates in a palliative care
setting (ECOG PS = 53–61 %; KPS = 38–50 %). There-
fore, there is a need for the development of new valid
scales or assessment strategies showing better inter-
observer reliability. Previously, other authors [3] devel-
oped an algorithm to more objectively measure PS based
on KPS. We used their work as a basic foundation for
developing our new strategy to evaluate PS using a flow-
chart. Unlike the aforementioned study, the Functionality
Assessment Flowchart (FAF) considers some patients’
responses and was developed based on the fundamental
aspects not only of the KPS, but also of the ECOG PS
and PPS. Our hypothesis was that the FAF, by contain-
ing patients’ opinions, would yield a higher inter-
observer reliability than other PS scales with similar
construct validity.
This preliminary study aimed to assess the PS of
patients with cancer using the FAF and evaluate the agree-
ment of scores measured by two independent raters.
Moreover, the agreement of FAF between observers and
its correlation with the functionality and fatigue scores
were compared with the results of the ECOG PS and KPS.
Methods
Study design and setting
A cross-sectional study was conducted in the Barretos
Cancer Hospital (Barretos, SP, Brazil). The patients were
recruited from the waiting rooms of the Breast and
Gynecology ambulatory.
Ethics statement
The local Research Ethics Committee approved the
present study (no. 644.297). In compliance with the
Declaration of Helsinki and Resolution 466/12 of the
Brazilian National Health Council, which addresses re-
search on human beings, the study aims were explained to
the participants, who then provided informed consent.
Development of the Functionality Assessment Flowchart
(FAF)
A detailed revision of the ECOG-PS, KPS and PPS was
performed by the authors to use pieces from each per-
formance status scale for the construction of a hybrid
tool that considers the patients’ opinions about their
own functionality. The authors conducted several meet-
ings to discuss instrument drafts until a final version
was considered adequate for testing. The FAF was
designed for systematic administration by an interviewer
and as a flowchart. The questions are highlighted in
blue; the flowchart ends after reaching any percentage.
The English version of the instrument is shown in Fig. 1
and the original Portuguese version in shown as Supple-
mentary Material (see Additional file 1).
Observers
Two medical graduate students and 5 medical oncolo-
gists participated in the study as observers. All of the
participants received printed scales and information
regarding the correct method to use the scales. Of note,
the medical graduate students were trained to evaluate
the patient’s PS using clinical simulated vignettes and
then observing one of the authors (CEP) in medical con-
sults for two consecutive weeks. High agreement rates
between medical graduate students and the advisor were
not considered a prerequisite for closing the pre-study
training. Nevertheless, it were required that the students
should memorize the scales; demonstrate familiarity with
them; and present logical explanations to justify every
chosen PS category. After reaching these criteria, the
medical students should be checked in additional 10
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evaluations maintaining the same standard to be consid-
ered ready to perform the study assessments.
Data collection
The observers were coded as observers A or B depend-
ing on personal availability. Observer A was always a
trained medical student, and observer B was a medical
oncologist; both of the observers evaluated patients
using the ECOG-PS, KPS and FAF. The evaluations
were independent, and the scales were used in a ran-
dom sequence. The Functional Assessment of Cancer
Therapy-Fatigue (FACT-F) questionnaire was applied by
observer A only after defining the PS score. Patients un-
able to answer the FACT-F questionnaire were evaluated
only regarding PS; in these cases, the FAF was answered
using information provided by the caregivers.
Instruments
The FACT-F questionnaire was specifically developed to
measure fatigue associated with anemia in cancer popu-
lations [10]. The FACT-F is a valid Brazilian, 40-item
instrument that contains the 27 items of FACT-G (sub-
divided into four primary domains of quality of life:
physical well being, social and family well being, emo-
tional well being, and functional well being) and 13
fatigue-related questions [11]. In patients with cancer,
the Functional Assessment of Chronic Therapy-Fatigue
(FACT-F) scale can differentiate patients by hemoglobin
level and patient-rated performance status [12]. In the
present study, we decided a priori to use the functional
well being scale (FWB) (range: 0–28), the fatigue sub-
scale (FS) (range: 0–52) and the FACT-F Trial Outcome
Index (TOI) (range: 0–108) as indicators of functionality.
Higher the scores indicated better functionally.
ECOG-PS is a measure of PS that ranges from 0 (fully
active) to 5 (dead) [5]. The KPS ranges from 100 %
(normal) to 0 % (dead) [4]. Translated Brazilian versions
of the ECOG-PS and KPS were used in the study. All of
the instruments were used in paper-and-pencil form.
Sample size estimation
The sample size was estimated considering 60 % and
85 % concordance rates for the KPS and FAF, respect-
ively. Using a significance level of 5 % for alpha and
20 % for beta, the sample size that was required for this
preliminary study was 76 patients.
Statistic analysis
Correlations were analyzed using Spearman’s rank cor-
relation coefficient. The concordance pattern was eval-
uated using both the unweighted and the weighted kappa
statistics; the strength of agreement was as follows:
<0.00 = poor agreement, 0.00–0.20 = slight agreement,
0.21–0.40 = fair agreement, 0.41–0.60 =moderate agree-
ment, 0.61–0.80 = substantial agreement, and 0.81–1.00 =
nearly perfect agreement [13]. The adopted significance
Fig. 1 English version of Functionality Assessment Flowchart (FAF). The questions are shown inside the blue squares. Responses are driven
according to the arrow direction as a flowchart. Final evaluation of performance status is shown in red numbers as percentage values
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level was 0.05. The statistical softwares used were SPSS
version 20.0 (SPSS; Chicago, IL, USA) and MedCalc Stat-




Between February 2014 and August 2014, 86 women were
invited to participate in the study. Of these women, 6
refused to participate due to extreme fatigue. Among the
80 women included in the study, 10 did not complete the
FACT-F due to poor clinical conditions.
The median age was 57 years (range, 30–80). Thirty-
six (n = 36, 45 %) women were married, 38 (47.5 %) were
studied for less than 8 years, and the majority (n = 60,
75.9 %) were inactive. The main primary tumor sites
were the breast (n = 55, 68.8 %), uterine cervix (n = 14,
17.5 %) and ovary (n = 4, 5 %). Thirty-nine (n = 39,
48.8 %) patients received some type of palliative therapy
for advanced cancer. Table 1 describes the primary
socio-demographic and clinical characteristics of the
evaluated patients.
Agreement between observers’ analyses
The overall absolute agreement rate between the ob-
servers was 49.4 % (39 of 79) for the KPS, 67 % (53 of
79) for the ECOG PS, and 78.2 % (61 of 78) for the FAF.
A comparison between the proportions indicated that
FAF presented a higher rate of agreement than the KPS
(Table 2). When using unweighted kappa values, inter-
observer reliability was “fair”, “moderate” and “substan-
tial” for KPS, ECOG PS and FAF, respectively. However,
when using weighted kappa values, the inter-observer
reliability results improved significantly, reaching sub-
stantial agreement for KPS and ECOG PS and nearly
perfect agreement for FAF (Table 2). All of the KPS,
ECOG PS and FAF pairings were highly significantly
correlated, with correlation coefficients of approxi-
mately 0.9 (Table 2).
Construct validity analyses
In general, the correlation coefficients between the FAF
and the FWB, FS and TOI scores were slightly higher
than those between the other PS scales with the FWB,
FS and TOI scores. However, all of the coefficients pre-
sented overlapping 95 % confidence intervals and should
thus be considered similar (Table 3).
Discussion
Cancer treatments are initiated and terminated based on
PS scores; inaccurate estimates may lead to a failure to
receive treatment that may be helpful or to a patient
receiving an aggressive treatment that should have been
avoided. Moreover, the PS is largely used to select
participants for inclusion in clinical trials. Thus, PS assess-
ment is an essential part of oncological care and must be
evaluated with high accuracy levels. In the present study,
we present a simple and reliable flowchart that considers
patient opinions and that demonstrates high absolute con-
cordance rates and good construct validity.
Table 1 Clinical and sociodemographic characteristics of the
patients (n = 80)
Characteristics N (%)
Age (years)
Median (range) 57.0 (30–80)






Years of formal education
Illiterate 10 (12.8)
Less than 8 28 (35.9)
8–11 28 (35.9)

















Adjuvant/neoadj chemotherapy 13 (16.3)
Adjuvant hormone therapy 17 (21.3)
Adjuvant trastuzumab 3 (3.8)
Palliative chemotherapy 28 (35.0)
Palliative hormone therapy 9 (11.3)
Radio chemotherapy 1 (1.3)
Palliative care only 2 (2.5)
SD standard deviation, NED no evidence of disease, Neoadj neoadjuvant
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The FAF is a new method to evaluate the PS of pa-
tients with cancer, compensating for the lack of instru-
ments to measure functionality in detail (on an 11-point
scale) with a high concordance rate between observers.
The absolute concordance rate in the present study
yielded nearly 80 % agreement, which was much higher
than the absolute agreement of the KPS (~50 %) and
ECOG-PS (67 %). Regarding the ECOG-PS, previous
studies found absolute agreement ranging from 40 % to
93 % [1, 9, 14, 15]. The inter-observer variability in-
creases as the number of choice increases [6]. Thus, the
absolute agreement rate of the KPS between observers is
generally lower than that of ECOG-PS, varying from
38 % to 76 % [1, 2, 9, 15].
Previous studies evaluated the agreement rates be-
tween observers by performing correlation analyses. In
general, high correlation coefficients (r > 0.80) have been
observed for ECOG-PS and KPS [2, 9, 16]. In accord-
ance with previous studies, we found Spearman correl-
ation coefficients of approximately 0.9 for all three of
the evaluated scales. Moreover, our study highlights that
high correlation levels are not necessarily associated with
high agreement between raters.
Although the overall percentage of agreement pro-
vides a measure of agreement, it does not consider the
agreement that would be expected purely by chance.
The kappa statistic, however, is a measure of “true”
agreement [17]. We found a clearly higher value of the
kappa statistic for FAF compared with that for KPS.
However, considering that our instruments are all or-
dinal multi-category scales, kappa can be weighted to
confer greater importance to large differences than
small differences between ratings. The KPS and FAF
weighted kappa values were similar, suggesting that the
disagreements between observers regarding KPS were pri-
mary small differences. The same pattern of improvement
in agreement values from unweighted to weighted kappa
were also observed by Meyers et al. [9].
One advantage of the FAF over the other tested scales
is that it considers the patient’s opinion about their
own functional states. As we hypothesized, the FAF can
improve the concordance rates between raters. How-
ever, some women could have inaccurately answered
the first step of the FAF (“Are you able to work or to
do your daily activities?”), causing secondary gains by
considering themselves worse (leave or absence from
work due to illness) or better (as a way to feel more
optimistic) than they actually were. FAF raters must
understand that the FAF is a flowchart developed to
facilitate PS evaluation and not a rigid measure based
strictly on patient responses.
The lack of a functional gold standard tool was a
challenge for this study. Thus, to evaluate the construct
validity of the FAF, we compared its scores with func-
tional and fatigue scores obtained from the previously
validated Brazilian version of the FACT-F questionnaire
[11]. As expected, the correlation between the functional
and fatigue scores and the PS scales was strong. Therefore,
in terms of construct validity, the FAF should be consid-
ered as valid as ECOG-PS and KPS.
Study limitations
This study was preliminary; therefore, one limitation
was its small sample size. Another significant limitation
is that all of the study assessments were performed re-
peatedly at the same ambulatory setting. Only female
participants were included, which potentially reduces
the generalizability of our results. Although we ana-
lyzed many low-functioning participants selected from
the waiting rooms, future studies should include a
greater sample of both outpatients and inpatients.
Table 2 Agreement analyses between different observers of the ECOG PS, KPS and FAF
PS Scales Agreement* (%) (95 % CI) Unweighted kappa (95 % CI) Weighted kappa (95 % CI) Spearman’s correlation (95 % CI)
ECOG-PS 67.0 (50.0–88.0) a, b 0.561 (0.427–0.695) 1 0.763 (0.679–0.847) 3 0.890 (0.833–0.928)
KPS 49.4 (35.1–67.5) b 0.396 (0.272–0.520) 2 0.747 (0.672–0.822) 3 0.905 (0.855–0.938)
FAF 78.2 (59.8–100) a 0.709 (0.600–0.819) 3 0.826 (0.741–0.911) 4 0.893 (0.837–0.930)
*Overall absolute agreement rate. Different letters indicate significant results (ECOG-PS versus KPS, p = 0.144; ECOG-PS versus FAF, p = 0.413; KPS versus FAF, p = 0.023).
1 Moderate agreement; 2 fair agreement; 3 substantial agreement; 4 nearly perfect agreement
Table 3 Spearman correlation analyses between performance status scores and functionality and fatigue scores from FACT-F
Correlation coefficients (95 % CI)
Domain ECOG-PS KPS FAF
FWB −0.640 (−0.727; −0.532) 0.656 (0.553; 0.741) 0.672 (0.583; 0.750)
FS −0.499 (−0.625; −0.344) 0.538 (0.392; 0.656) 0.574 (0.435; 0.676)
TOI −0.606 (−0.714;-0.472) 0.639 (0.509; 0.736) 0.680 (0.569; 0.756)
FWB functional wellbeing, FS fatigue subscale, TOI trial outcome index
The results were significant at <0.001
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Future perspectives
Our preliminary findings support a subsequent study
with a larger and heterogeneous sample size to more
definitively investigate the benefit of implementing a PS
assessment using the FAF in clinical practice. We are
currently developing a computational software contain-
ing the FAF and intend to assess its construct validity
by comparing its values with more precise functional
activity levels measured by digital accelerometers [18].
We consider both the ECOG-PS and KPS to be well-
established tools in the oncology setting. However, the
FAF has the advantage of evaluating the PS in a more dis-
criminative manner than the ECOG-PS and with a higher
concordance rate than KPS. Thus, the FAF is a new tool
that requires further refinement and investigation.
Conclusions
We present a new simple and reliable instrument to meas-
ure the PS in cancer patients. The FAF demonstrated good
inter-observer agreement and adequate construct validity.
The FAF is a potential new tool to assess the PS with high
agreement between observers. Further studies are neces-
sary to investigate the FAF in other settings using more-
practical computational software.
Additional file
Additional file 1: Original version (Portuguese from Brazil) version
of Functionality Assessment Flowchart (FAF).
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